SecBot SecBot

UPB

Upstream Bio, Inc.
Nasdaq· Pharmaceutical Preparations· Inc. DE· CIK 0002022626 Biotech & Drug Discovery
$2.79 +0.04 (+1.45%)
Oct 27 4:00 PM ET · prev $2.75
Market cap
$150.1M
Micro cap
Consensus
Buy
75% Buy or better · 12 analysts
Median target
$22.00
+689% · range $9.00–75.00
Next earnings
Nov 5
in 8 days · EPS est. −$0.73
1 year
−88.8%
from $24.84 · Oct 28
30 days
−47.4%
from $5.30
52-week range
$2.74–32.60
−91% from high · low Oct 23
Avg volume 20D
1.28M
shares / day
Short interest
4.48M
≈8.2% of shares · −0.8%
Days to cover
3.7
at average volume
Insider net
−$104.8K
0 buyers · 5 sellers · 12 mo
New fund stakes
0
Q2 2026 13F · 0 exits
SecBot read BULLISH 2 reports · 90 days
Balance 0 bearish · 1 bullish · 1 neutral oldest → newest, height = score
Avg score ·High conf. 2/2 ·Next Earnings date, Nov 5, 2026
Strongest BULLISH Upstream Bio announced pivotal Phase 3 development plans for verekitug in severe asthma and CRSwNP following…
All reports →

Price

Daily candles with volume. Pins mark insider trades, rating changes, 13F stakes, reports, catalysts and short-interest jumps.

Signal stack

Where each data set points today.

  • InsidersBEARISH

    5 insiders sold $104.8K.

  • InstitutionsBULLISH

    Q2 2026: 28 added (0 new), 6 trimmed or exited.

  • AnalystsBULLISH

    9 of 12 rate it Buy or better. Every target is above the price.

  • EstimatesFALLING

    Current-quarter EPS estimate −$0.710 → −$0.729 over 90 days. 4 up, 3 down in 30 days.

  • Short sellersSTEADY

    Short interest −0.8% to 4.48M shares. 3.7 days to cover, ≈8.2% of shares.

  • TrendDOWNTREND

    46% below its 50-day average. New closing low $2.74 on Oct 23.

Who's buying

13F· Q2 2026
0
new positions
0
exits
FundMoveSharesValue
NORGES BANKADD3,768,619$26.1M
D. E. Shaw & Co., Inc.ADD1,036,044$7.2M
JPMORGAN CHASE & CODOUBLED1,012,044$7.0M
Qube Research & Technologies LtdADD978,500$6.8M
BNP PARIBAS FINANCIAL MARKETSDOUBLED511,546$3.5M
Trexquant Investment LPDOUBLED466,430$3.2M
Point72 Asset Management, L.P.DOUBLED453,011$3.1M
BANK OF AMERICA CORP /DE/DOUBLED391,762$2.7M

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

12 analysts
Buy 75% rate it Buy or better
Strong Buy2Buy7Hold3Sell0Strong Sell0
12-month targets · 6 analysts

Price is below the lowest target. Median implies +689%.Targets as of Oct 28, 2026.

Recent actions
DateFirmActionRating
Sep 2, 2026HC Wainwright & Co.
REITERATE
REITERATEBuy
Aug 14, 2026JP Morgan
MAINTAIN
MAINTAINNeutral
Aug 12, 2026Truist Securities
MAINTAIN
MAINTAINBuy
Jun 12, 2026JP Morgan
DOWNGRADE
DOWNGRADENeutral
Jun 3, 2026HC Wainwright & Co.
INITIATE
INITIATEBuy
May 14, 2026Mizuho
MAINTAIN
MAINTAINOutperform

Insider ledger

Form 4
$0
bought · 0 insiders
$104.8K
sold · 5 insiders
DateInsiderTypeValue
Sep 16, 2026
GRAY MICHAEL
CFO and COO
SELL$4.7K
Sep 16, 2026
Sutherland Everett Rand
Chief Executive Officer
SELL$11.5K
Sep 16, 2026
Houghton Adam
Chief Business Officer
SELL$3.8K
Sep 16, 2026
Deykin Aaron
Chief Medical Officer
SELL$4.9K
Sep 16, 2026
Ambrose Allison
General Counsel
SELL$2.7K
Jun 16, 2026
Deykin Aaron
Chief Medical Officer
SELL$5.5K
Jun 16, 2026
Ambrose Allison
General Counsel
SELL$2.9K
Jun 16, 2026
GRAY MICHAEL
CFO and COO
SELL$5.2K

Earnings setup

Estimates
Nov 5
reports in 8 days
−$0.73
EPS estimate, this quarter
−3%
estimate change, 90 days
4↑ 3↓
revisions, 30 days
Current-quarter EPS estimate
PeriodEPS est.Range30D rev.Revenue
Current Q-$0.73-$0.88–-$0.52-4.3%$480.3K
Next Q-$0.73-$0.95–-$0.42-7.8%$483.6K
Current FY-$2.90-$3.26–-$2.17-2.2%$2.7M
Next FY-$2.80-$3.46–-$1.77+3.0%$1.4M

Short side

FINRA· Oct 15, 2026
4,480,785
shares short
-0.8%
vs prior settlement
3.7
days to cover
≈8.2%
of shares outstanding
Recent activity
The latest filings, insider trades, analyst actions, press and options flow, newest first.
Sep 16, 2026 Insider
GRAY MICHAEL sold 853 shares
CFO and COO @ $5.49 ($4.7K)
Sep 16, 2026 Insider
Sutherland Everett Rand sold 2,095 shares
Chief Executive Officer @ $5.49 ($11.5K)
Sep 16, 2026 Insider
Houghton Adam sold 700 shares
Chief Business Officer @ $5.49 ($3.8K)
Sep 8, 2026 FDA
Upstream Bio Presents Results from the Phase 2 VALIANT Trial of Verekitug for the Treatment of Severe Asthma in Oral Presentation at ERS Congress 2026
– Verekitug, 100 mg dosed every 12 weeks, reduced AAER by 56% compared to placebo in patients with s
Sep 1, 2026 SEC
Upstream Bio announced pivotal Phase 3 development plans for verekitug in severe asthma and CRSwNP following…
8-K · Impact 7/10
Aug 11, 2026 SEC
Upstream Bio reported Q2 2026 financial results with a net loss of $39.7M, roughly in line with the $40.0M loss in Q2…
8-K · Impact 4/10
Jun 30, 2026 Inst.
NORGES BANK · ADD
3,768,619 shares ($26.1M)
Jun 30, 2026 Inst.
D. E. Shaw & · ADD
1,036,044 shares ($7.2M)
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
Upcoming
Nov 5, 2026
Earnings date
UPB Q3 2026 Earnings Scheduled · 2026-11-05
Recent
Sep 18, 2026
Clinical Trial
A Study to Investigate the Efficacy and Safety of Verekitug (UPB-101) in Participants With Chronic Rhinosinusitis With Nasal Polyps
Phase 2 · COMPLETED
Sep 8, 2026
FDA
Upstream Bio Presents Results from the Phase 2 VALIANT Trial of Verekitug for the Treatment of Severe Asthma in Oral Presentation at ERS Congress 2026
– Verekitug, 100 mg dosed every 12 weeks, reduced AAER by 56% compared to placebo in patients with severe asthma –
Aug 12, 2026
Earnings date
UPB Q2 2026 Earnings Scheduled — 2026-08-12
Aug 11, 2026
Earnings
Upstream Bio Reports Second Quarter 2026 Financial Results and Highlights Continued Progress
– Company rapidly advancing toward Q1 2027 initiation of Phase 3 trials designed to deliver best-in-class efficacy with convenient quarterly dosing…
Aug 4, 2026
Earnings date
UPB Q2 2026 Earnings Scheduled — 2026-08-04

SecBot reports

6 filings · 5 press releases · 1 bullish · 2 bearish · 3 neutral
All UPB filing & press-release reports (11)